hrp0089p2-p354 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P2 | ESPE2018

Etiology of Disorders of Sex Development in Kenyan Children and Adolescents

Amolo Prisca , laigong Paul , Omar Anjumanara , Drop Stenvert

Objective: The purpose of this study was to describe baseline data on etiological diagnosis of Disorders of Sex Development (DSD) in Kenyan children and adolescents.Methods: This retrospective study included 71 patients diagnosed with DSD who presented at ages 0–19 years from January 2008 to December 2015 at the Kenyatta National (KNH) and Gertrude’s Children’s (GCH) Hospitals.Results: Thirty-nine (54.9%) children ha...

hrp0089p3-p326 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology P3 | ESPE2018

Clinical Presentation and Characteristics of DSD in Kenyan Children and Adolescents

Omar Anjumanara , Amolo Prisca , Laigong Paul , Drop Stenvert

Study Objective: To describe the clinical presentation and characteristics of DSD in Kenyan children and adolescents.Methodology: This retrospective observational study was carried out at Kenyatta National hospital and Gertrude’s Children’s Hospitals involving 71 patients age 0–19 years with DSD enrolled in the clinics between January 2008 to December 2015.Results: The mean age at the time of diagnosis was 2.7 years ...

hrp0082p2-d3-311 | Bone (2) | ESPE2014

Hyperostosis-Hyperphosphataemia Syndrome: Shortening a Diagnostic Odyssey

Kothandapani Jaya Sujatha Gopal , Offiah Amaka , Hobson Sally , Arundel Paul

Introduction: Hyperostosis-hyperphosphataemia syndrome (HHS) is a rare autosomal recessive condition caused by inactivating mutations in the GALNT3 gene, characterised by elevated serum phosphate and 1,25(OH)2 vitamin D, increased urinary tubular reabsorption of phosphate and hyperostosis of long bones.Case report: A 15-year-old boy (weight +1.05 SD; height −0.1 SD) with consanguineous parents of Palestinian descent, presented w...

hrp0082p3-d1-665 | Bone | ESPE2014

Survey of Vitamin D Status in Breastfeeding Infants Under the Age of 6 Months Attending the Growth Monitoring Clinic at Rubaga Hospital

Cissy Nalunkuma , Paul Laigong , Edison Mworozi , Fox Larry

Background: Vitamin D deficiency has been found to occur in peoples of all ages worldwide, including those living in sunny climates. Sun exposure is the main source of this vitamin for many people but its utilization is influenced by many factors such as lifestyles and availability of sunlight. The breastfeeding infant is particularly at increased risk of deficiency because of its dependence on maternal stores.Objective and hypotheses: The hypothesis for...

hrp0082p3-d3-727 | Diabetes (2) | ESPE2014

Evaluation of HbA1c Measurement in Trinidad and Tobago

Rastogi Maynika , Ladenson Paul , Goldstein David , Little Randie

Introduction: The prevalence of diabetes in Trinidad and Tobago (T&T) exceeds 12%. Monitoring of HbA1c is standard of care to assess diabetes control but assay reliability requires high precision and standardization to either DCCT or IFCC values and results should be monitored through proficiency testing (PT). In T&T a developing country there is no existing data on HbA1c precision and accuracy. Johns Hopkins Medicine International and the Diabetes Diagnostic Laborator...

hrp0097p1-483 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Incidence of Perinatal Stress Hyperinsulinism Requiring Diazoxide Treatment in Newborn Infants

Rafferty Deborah , Truong Lisa , Nedrelow J , Thornton Paul

Background: The incidence of perinatal stress hyperinsulinism (PSHI) requiring diazoxide treatment is estimated to be 1:12,000 (Hoe et al., 2006). Diazoxide is used to treat PSHI, but it has been shown to have adverse effects including pulmonary hypertension. Gray et al, reported that of 1.25 million infants admitted to NICUs for hypoglycemia over a period of 18 years, only 1066 received diazoxide suggesting 1:1172 babies had HI however 92% o...

hrp0097p1-336 | Multisystem Endocrine Disorders | ESPE2023

Clinical presentation and incidence trends of paediatric endocrine conditions at a tertiary referral and teaching hospital, Nairobi, Kenya. a 14 year retrospective study from 2008 to 2021.

Wamalwa Phoebe , Mungai Lucy , Laigong Paul , Omar Anjum , Amolo Prisca

Background: There is significant disparity in pediatric endocrinology and diabetes care between developed countries and developing countries. Over the years nevertheless, the diagnosis and management of pediatric endocrine conditions has improved. However, there is paucity of data on clinical presentation and incidence trend amongst pediatric endocrine conditions in sub-Saharan Africa.Methods: A hospital-based retrospect...

hrp0097p1-570 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Elucidating The Genetic Basis of Human Disorders of Sex Development Using Clinic-To-Bench Approach

Florsheim Natan , Renbaum Paul , Levy-Lahad Ephrat , Zangen David

Background: Diseases of sex development (DSD) are rare heterogeneous disorders ranging from infertility (an estimated 15% of couples worldwide have difficulty conceiving), to severe cases including ambiguous genitalia, sex reversal, and gonadal dysgenesis. The genetic basis of DSD remains unknown in 50% of the severe cases. To identify novel genetic causes of DSD, we are investigating patients in which known causative genes have been excluded. Identifying new ...

hrp0094p1-161 | Growth B | ESPE2021

Continued Safety and Efficacy of Weekly Lonapegsomatropin (TransCon hGH) for up to Two Years in Children with Growth Hormone Deficiency (GHD)

Aghajanova Elena M. , Casella Samuel J. , Nadgir Ulhas , Hofman Paul , Saenger Paul , Song Wenjie , Mao Meng , Chessler Steven , Komirenko Allison S. , Beckert Michael , Shu Aimee D. , Thornton Paul S. , Maniatis Aristides K. ,

Lonapegsomatropin (TransCon hGH) is an investigational once-weekly prodrug of somatropin for the treatment of GHD. Previous trials in treatment-naïve (52-week heiGHt Trial) and treatment-experienced children (26-week fliGHt Trial) have reported the efficacy and safety of lonapegsomatropin. Subjects were eligible to enter the open-label extension enliGHten Trial, which continues to evaluate weekly lonapegsomatropin in pediatric GHD. In heiGHt, treatment-naïve subjects...

hrp0094p2-367 | Pituitary, neuroendocrinology and puberty | ESPE2021

Duplication of Pituitary Gland-plus Syndrome presenting with a Transcranial Nasal Dermoid Cyst

Chandwani Manju , Spilioti Diamantina-Xanthi , Chumas Paul , Symth Alistair , Alvi Sabah , Nix Paul , Warren Daniel , Liddington Mark , Russell John , Elliott Mark ,

Duplicated pituitary gland in association with other midline craniofacial anomalies – also described as DPG-plus syndrome – is extremely rare. So far the only described endocrine associations are precocious or delayed puberty. We describe the multifaceted management of a female infant with DPG-plus syndrome. Interestingly, the patient also presented with trans-cranial nasal dermoid cyst and a nasal dimple with protruding hair, which has not been described in previous...